Rapamycin Sensitizes Glucocorticoid Resistant Acute Lymphoblastic Leukemia CEM-C1 Cells to Dexamethasone Induced Apoptosis Through Both MTOR Suppression and Up-regulation and Activation of Glucocorticoid Receptor
Overview
Affiliations
Objective: To explore the role of glucocorticoid (GC) receptor (GR) in rapamycin's reversion of GC resistance in human GC-resistant T-acute lymphoblastic leukemia (ALL) CEM-C1 cells.
Methods: CEM-C1 cells were cultured in vitro and treated with rapamycin at different concentrations with or without 1 μmol/L dexamethasone (Dex). 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) test was performed to assess cell proliferation. The cell cycle and cell apoptosis were analyzed by flow cytometry. The expression of GRα mRNA was determined by real-time quantitative RT-PCR. The expression of GR, p-70S6K, Mcl-1, and Bim proteins was detected by Western blot.
Results: When incubated with rapamycin at different concentrations, CEM-C1 cells showed significant growth inhibition in a time- and concentration-dependent manner. The growth inhibition was synergistically increased when CEM-C1 cells were treated with rapamycin plus 1 μmol/L Dex. CEM-C1 cells treated with rapamycin alone showed no apparent apoptosis, and were arrested at G0/G1 phase. After the treatment with Dex plus rapamycin, CEM-C1 cells demonstrated apparent apoptosis and increased the cell cycle arrested at G0/G1 phase. Rapamycin combined with Dex up-regulated GRα, phosphorylated GR(p-GR), and pro-apoptotic protein Bim-EL in CEM-C1 cells, but inhibited the expression of p-p70S6K, a downstream target protein of mTOR (mammalian target of rapamycin).
Conclusion: After the treatment with rapamycin plus Dex, Dex resistant CEM-C1 cells induce growth inhibition and apoptosis. The underlying mechanism may involve inhibition of the mTOR signaling pathway and also be associated with up-regulation of GR expression and activation of GC-GR signaling pathway.
Exploring the nexus of nuclear receptors in hematological malignancies.
Manickasamy M, Sajeev A, BharathwajChetty B, AlQahtani M, Abbas M, Hegde M Cell Mol Life Sci. 2024; 81(1):78.
PMID: 38334807 PMC: 10858172. DOI: 10.1007/s00018-023-05085-z.
Anti-Leukemic Effects of Maxim Branch on Human B-Cell Acute Lymphoblastic Leukemia Cells.
Kwon C, Lee J, Jeon B, Woo Y, Kim Y, Kim J Curr Issues Mol Biol. 2023; 45(5):4035-4049.
PMID: 37232726 PMC: 10217017. DOI: 10.3390/cimb45050257.
LRH-1/NR5A2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance.
Michalek S, Goj T, Plazzo A, Marovca B, Bornhauser B, Brunner T EMBO Rep. 2022; 23(9):e54195.
PMID: 35801407 PMC: 9442305. DOI: 10.15252/embr.202154195.
Lucafo M, Sicari D, Chicco A, Curci D, Bellazzo A, Di Silvestre A Cancer Chemother Pharmacol. 2020; 86(3):361-374.
PMID: 32776229 PMC: 7479018. DOI: 10.1007/s00280-020-04122-z.
Chen Y, Jiang P, Wen J, Wu Z, Li J, Chen Y Cancer Med. 2020; 9(8):2918-2929.
PMID: 32096603 PMC: 7163086. DOI: 10.1002/cam4.2934.